Clinical trial
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated…
NCT00061763 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00061763 |
|---|---|
| Title | Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias |
| Official title | Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Beta-thalassemia, Myelodysplastic Syndromes, Fanconi Syndrome, Anemia, Diamond-Blackfan, Aplastic |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 175 |
| Start date | May 1, 2003 |
| Primary completion | Nov 1, 2004 |
| First posted | Jun 4, 2003 |
| Last update posted | Aug 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: